Published in Oncotarget on July 10, 2015
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys (2016) 0.80
Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia. Diagn Pathol (2015) 0.76
Differential Impacts of Alternative Splicing Networks on Apoptosis. Int J Mol Sci (2016) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem (1993) 11.44
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell (2005) 3.18
Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo (2008) 3.13
hnRNP K: one protein multiple processes. Bioessays (2004) 2.96
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta (2005) 2.15
ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol (2001) 2.14
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol (2011) 2.09
Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. PLoS Genet (2010) 1.76
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer (2006) 1.65
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood (2005) 1.56
hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol (2005) 1.50
Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res (2009) 1.44
Quantification of gamma-H2AX foci in human lymphocytes: a method for biological dosimetry after ionizing radiation exposure. Radiat Res (2010) 1.42
Mitogen-activated protein kinases and their role in radiation response. Genes Cancer (2013) 1.26
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Poly(C)-binding proteins as transcriptional regulators of gene expression. Biochem Biophys Res Commun (2009) 1.20
Gamma-H2AX-based dose estimation for whole and partial body radiation exposure. PLoS One (2011) 1.18
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
ATM-dependent phosphorylation of heterogeneous nuclear ribonucleoprotein K promotes p53 transcriptional activation in response to DNA damage. Cell Cycle (2013) 1.10
Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem (2013) 1.03
The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ (2010) 1.01
Establishment and characterization of human ocular melanoma cell lines. Int J Cancer (1993) 1.00
Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene (2009) 0.98
Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol (2011) 0.97
Evidence for heterogeneous nuclear ribonucleoprotein K overexpression in oral squamous cell carcinoma. Br J Cancer (2007) 0.95
Characterization of hnRNP K protein-RNA interactions. J Mol Biol (2004) 0.93
Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma. Ann Surg Oncol (2010) 0.91
Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res (2009) 0.90
Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One (2013) 0.89
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol (2014) 0.88
hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors. Carcinogenesis (2013) 0.84
Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol (2011) 0.82
Thymidine phosphorylase inhibits apoptosis induced by cisplatin. Biochem Biophys Res Commun (2003) 0.82
Induction of gamma-H2AX foci in human exfoliated buccal cells after in vitro exposure to ionising radiation. Int J Radiat Biol (2010) 0.81
DNA damage focus analysis in blood samples of minipigs reveals acute partial body irradiation. PLoS One (2014) 0.81
The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.77
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol (2012) 0.77